Patents by Inventor Diem Vu

Diem Vu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952421
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Publication number: 20240054231
    Abstract: To decrease development revision cycle time and reduce deployment and execution errors when porting software from a public cloud to a specialized cloud, the software is analyzed for certain characteristics. Analysis may check for non-permitted items, required items, fragile code, morph code, or deny list expressions, for example. The particular items, codes, expressions, or other characteristics targeted by analysis derive from gapping constraints that distinguish the specialized cloud from public clouds, such as an air-gap constraint, a geolocation constraint, or a government security constraint. Software cloud compatibility analyses may be added, removed, or updated using a modular framework architecture, using declarative analysis module declarations, or both. False positive analysis results may be filtered out. Analysis results may include suggestions.
    Type: Application
    Filed: August 15, 2022
    Publication date: February 15, 2024
    Inventors: James Michael LIMONES, Garrett Christopher HALEY, Steven Alexander MARTINEZ, Keith Robert Joseph HITCHCOCK, Alexis Kristen Phuong Diem VU, Trevor DANIELSON, Cristian NITULESCU
  • Publication number: 20230322957
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: November 21, 2022
    Publication date: October 12, 2023
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20230057602
    Abstract: The present invention relates to methods of treating a patient having a disorder associated with BCMA expression (e.g. BCMA-expressing B-cell cancers, such as multiple myeloma) using dose-escalation dosing regimens with multispecific (e.g. bispecific) antibodies that bind to CD3 and BCMA.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 23, 2023
    Inventors: Michael BURGESS, Kristen HEGE, Kaushik DATTA, Isaac BOSS, Minh Diem VU
  • Publication number: 20220017631
    Abstract: The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 20, 2022
    Inventors: Minh Diem Vu, Klaus Strein, Bruno David Lourenco Paiva, Jesus Fernado San Miguel Izquierdo
  • Publication number: 20220002427
    Abstract: The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 6, 2022
    Inventors: Minh Diem Vu, Klaus Strein, Bruno David Lourenco Paiva, Jesus Fernado San Miguel Izquierdo
  • Patent number: 11124577
    Abstract: The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 21, 2021
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Bruno David Lourenco Paiva, Jesus Fernado San Miguel Izquierdo
  • Publication number: 20210070873
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 11, 2021
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20200385471
    Abstract: The disclosure relates to bispecific antibodies against CD3? and BCMA for use in the treatment of diseases. The disclosure provides methods of determining the responsiveness of a patient to such treatment and relates to diagnostic assays.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 10, 2020
    Inventors: Minh Diem Vu, Klaus Strein, Erich Hunziker
  • Patent number: 10851171
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: December 1, 2020
    Assignee: ENGMAB SARL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20200283545
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: March 17, 2020
    Publication date: September 10, 2020
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20200255521
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? (further named also as “CD3”) and the extracellular domain of human ROR1 (further named also as “ROR1”), characterized in that the bispecific antibody does not internalize in a cell based assay at 37° C. during 2 hrs, using ROR1-positive B-CLL cells and used at an antibody concentration of 1 nM, whereby not internalize means, that the mean fluorescence intensity (MFI), as detected by flow cytometry, of a bispecific antibody upon binding to ROR1-positive primary B-CLL cells measured at time 0 is not reduced for more than 50%, preferably not more than 30% when re-measured after a 2 hr-incubation at 37° C. and which is useful for the treatment of B-cell malignancies like Chronic Lymphocytic Leukemia or B-cell disorders expressing ROR1 and ROR1-positive solid tumors.
    Type: Application
    Filed: January 27, 2020
    Publication date: August 13, 2020
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Tanja Fauti, Ramona Murr, Christian Klein, Pablo Umana, Samuel Moser
  • Patent number: 10683369
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 16, 2020
    Assignee: EngMab Sàrl
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20190352427
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: August 3, 2016
    Publication date: November 21, 2019
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Duerner, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20190263920
    Abstract: The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.
    Type: Application
    Filed: November 2, 2017
    Publication date: August 29, 2019
    Applicant: ENGMAB SARL
    Inventors: Minh Diem Vu, Klaus Strein, Bruno David Lourenco Paiva, Jesus Fernado San Miguel Izquierdo
  • Patent number: 10253104
    Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3?, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: April 9, 2019
    Assignee: ENGMAB AG
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Lydia Jasmin Hanisch, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Patent number: 10077315
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: September 18, 2018
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20180222991
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Inventors: Minh Diem VU, Klaus STREIN, Ekkehard MOESSNER, Ralf HOSSE, Oliver AST, Anne FREIMOSER-GRUNDSCHOBER, Marina BACAC, Tanja FAUTI, Christian KLEIN, Pablo UMANA, Samuel Moser
  • Patent number: 9963513
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 8, 2018
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20170327579
    Abstract: A bispecific antibody specifically binding to the extracellular domain of human BCMA and human CD3?, characterized in comprising a common antibody light chain is provided. Such bispecific antibody can be used as a medicament in the treatment of plasma cell disorders like Multiple Myeloma.
    Type: Application
    Filed: November 18, 2015
    Publication date: November 16, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, MARINA BACAC, PETER BRUENKER, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RAFT HOSSE, ADRIAN HUGENMATTER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, Samuel MOSER, Pablo UMANA